Nestlé has reportedly embarked on looking for buyers for Palforzia, the peanut-allergy business bought three years ago.
According to Bloomberg, which cited unnamed sources, the Swiss giant has hired investment bankers at Evercore to see what interest there is in the unit.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In November, Nestlé said it was looking at its “strategic options” for Palforzia, which was part of the California-based Aimmue Therapeutics business of which the KitKat maker took full control in 2020. It had first invested in Palforzia four years earlier.
Announcing the review, the world’s largest food maker emphasised “its longstanding nutrition, health and wellness strategy” but said Palforzia had seen “slower-than-expected adoption by patients and healthcare professionals”.
The company added at the time: “Going forward, Nestlé Health Science will sharpen its focus on consumer care and medical nutrition.”
Earlier this week, it emerged Nestlé had bought a minority stake in German nutrition-based start-up YFood.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Munich-based company markets meal-replacement snack bars, drinks and powders.
